Although HIV infection has been reported to have little impact on leprosy, initiation of antiretroviral treatment has been associated with activation of subclinical Mycobacterium leprae infection and exacerbation of existing leprosy lesions . Since the introduction of HAART for AIDS treatment, 17 cases of leprosy reaction associated with immune reconstitution inflammatory syndrome (IRIS) have been described in the literature [2–12]. The present study describes 10 cases of IRIS-associated reversal reaction in a cohort with 28 coinfected HAART patients diagnosed with leprosy from 1996 to 2007 at the Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. Pertinent data on these patients were collected from patient charts. Case reports of two of these patients have been published ; but since additional data were added, they were maintained in the cohort.
Leprosy was diagnosed and classified according to Ridley–Jopling criteria . The histopathological definition of reversal reaction was primarily based on the presence of epithelioid-cell granuloma. Reversal reaction treatment and HIV diagnosis followed the Brazilian Ministry of Health regulations [14,15]. HAART was initiated when the CD4 cell count was 200 cells/μl or less or if an opportunistic infection was diagnosed. IRIS was defined as the presence of reaction during the first 6 months of HAART in association with a decrease of more than 1 log in the HIV-1 viral load , or when naive patients with no laboratory test data previous to HAART initiation were found to have an undetectable HIV-1 viral load at the onset of reversal reaction.
Among the 28 patients experiencing leprosy reversal reaction under HAART, 10 (36%) met the predetermined IRIS criteria. Demographic, clinical, and laboratory data of these 10 IRIS patients are presented in Table 1. Eight patients were initially diagnosed with HIV. Significantly, HAART induced reaction in seven patients who had not been diagnosed with leprosy. The mean time the patients presented reversal reaction after starting HAART was 7.8 weeks.
The clinical or laboratory findings of all patients showed immune suppression prior to reversal reaction diagnosis. Moreover, by the time reaction occurred during HAART treatment, all patients had an increased CD4/CD8 T-lymphocyte rate, mainly due to an increased CD4 cell count mean of 170 cells/μl (92–357 cells/μl). Seven patients had an undetectable viral load when reaction developed and three had a mean viral load reduction of 2.4 log (1.4–4.6 log). All patients were treated for HIV with regimens containing two nucleoside reverse transcriptase inhibitors in combination with a protease inhibitor (10%), a boosted protease inhibitor (40%), or a nonnucleoside reverse transcriptase inhibitor (50%).
All patients presented erythematous-infiltrated plaques. The histopathological features observed in the skin biopsies ranged from heavy infiltration, necrosis foci, and extensive epidermal involvement to mild infiltration with small, well formed granulomas. Four biopsies showed evidence of fragmented acid-fast bacilli.
Eight patients received standard treatment for reaction in addition to the multidrug therapy for leprosy. Three patients required prolonged use of prednisone for up to 11 months.
As observed in the present case series, in the HAART era, leprosy reaction associated with IRIS appears to be a frequent event in coinfected patients. The 36% reversal reaction rate in coinfected patients undergoing HAART is similar to that estimated for tuberculosis as a manifestation of IRIS [17,18]. Interestingly, HAART triggered reversal reaction in 88% of the patients not previously known to have leprosy. As likewise seen in the literature, most of the present IRIS cases associated with leprosy had the predominantly borderline-tuberculoid form [2–12]. The borderline forms are considered the most unstable in that the immunological capability of the patient to restrain the infection is only partial. During reversal reaction, high amounts of inflammatory cytokines such as interferon-γ and tumor necrosis factor are produced, reflecting the immune activation characteristics of skin lesions with a tuberculoid pattern .
Furthermore, immune restoration by HAART does appear to worsen reversal reaction. In the present series, 60% of the patients had numerous lesions, 30% had skin ulcers, and 30% needed extended corticoid therapy, demonstrative of a more intense inflammatory process. This type of presentation is more commonly seen in type II leprosy reactions, which are more frequent in multibacillary patients and which have never been referred to in the context of IRIS. On the other hand, patients with the tuberculoid forms, who tend to display a strong cellular response to M. leprae, are more often found to have neuritis. Therefore, it is surprising that only one patient in this series was diagnosed with neuritis.
The histological findings observed in all patients were typical of reversal reaction. Disorganized and disperse granulomas could be seen in some cases, thus making it difficult to classify them according to the Ridley and Jopling leprosy spectrum. The presence of necrosis only occurred during severe reaction, either in small foci or when causing liquefaction of the granuloma followed by fibrosis, as seen in one case. The presence of a small number of acid fast bacilli has already been described in borderline tuberculoid lesions .
It is worth noting that in the present series, patients treated with prednisone as standard reversal reaction therapy had a favorable evolution despite disease severity. Thus, the results of this study clearly indicate that no modification of the standard reversal reaction therapy appears necessary in leprosy patients with IRIS.
In countries like Brazil, where both epidemics overlap and HAART has been broadly administered, leprosy reaction associated with IRIS is prone to occur. It might be posited, therefore, that the appearance of clinical signs of M. leprae infection in HIV-infected individuals is not a manifestation of immune suppression but rather of immune reconstitution. However, further prospective studies are required to more adequately evaluate the association of leprosy reaction and IRIS so as to more precisely characterize the pathology and immunology of this worrisome coinfection.
We would especially like to thank Judy Grevan for editing the text.
E.S. supervised this work. M. M. generated the CD4+ cell count and viral load data. A. M. generated the histopathologic data. X. I. carried out the statistical analysis. A. S., M.C.G., J.A.N., and V.M. were treating physicians of the patients and collected clinical data. All coauthors contributed to the development and critical revision of the article.
1. Sarno EN, Illarramendi X, Nery JA, Sales AM, Gutierrez-Galhardo MC, Penna ML, et al
. HIV-M. leprae
interaction: can HAART modify the course of leprosy? Public Health Rep 2008; 123:206–212.
2. Lawn SD, Wood C, Lockwood DN. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin Infect Dis 2003; 36:e5–e6.
3. Couppie P, Abel S, Voinchet H, Roussel M, Helenon R, Huerre M, et al
. Immune reconstitution inflammatory syndrome associated with HIV and leprosy. Arch Dermatol 2004; 140:997–1000.
4. Pereira GA, Stefani MM, Araujo Filho JA, Souza LC, Stefani GP, Martelli CM. Human immunodeficiency virus type 1 (HIV-1) and Mycobacterium leprae
co-infection: HIV-1 subtypes and clinical, immunologic, and histopathologic profiles in a Brazilian cohort. Am J Trop Med Hyg 2004; 71:679–684.
5. Pignataro P, Rocha Ada S, Nery JAC, Miranda A, Sales AM, Ferreira H, et al
. Leprosy and AIDS: two cases of increasing inflammatory reactions at the start of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2004; 23:408–411.
6. Visco-Comandini U, Longo B, Cuzzi T, Paglia MG, Antonucci G. Tuberculoid leprosy in a patient with AIDS: a manifestation of immune restoration syndrome. Scand J Infect Dis 2004; 36:881–883.
7. Narang T, Dogra S, Kaur I. Borderline tuberculoid leprosy with type 1 reaction in an HIV patient – a phenomenon of immune reconstitution. Int J Lepr Other Mycobact Dis 2005; 73:203–205.
8. Singal A, Mehta S, Pandhi D. Immune reconstitution inflammatory syndrome in an HIV seropositive leprosy patient. Lepr Rev 2006; 77:76–80.
9. Kharkar V, Bhor UH, Mahajan S, Khopkar U. Type I lepra reaction presenting as immune reconstitution inflammatory syndrome. Indian J Dermatol Venereol Leprol 2007; 73:253–256.
10. Talhari C, Machado PR, Ferreira LC, Talhari S. Shifting of the clinical spectrum of leprosy in an HIV-positive patient: a manifestation of immune reconstitution inflammatory syndrome? Lepr Rev 2007; 78:151–154.
11. Batista MD, Porro AM, Maeda SM, Gomes EE, Yoshioka MC, Enokihara MM, et al
. Leprosy reversal reaction as immune reconstitution inflammatory syndrome in patients with AIDS. Clin Infect Dis 2008; 46:e56–e60.
12. Deps PD, Gripp CG, Madureira BP, Lucas EA. Immune reconstitution syndrome associated with leprosy: two cases. Int J STD AIDS 2008; 19:135–136.
13. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five group system. Int J Lepr Other Mycobact Dis 1966; 34:255–273.
14. Secretaria de Vigilância Epidemiológica. Guide to Epidemiological Surveillance
. Brazil: Ministry of Health of Brazil; 2005:1–33.
15. National STD and AIDS program of Brazil. Recommendations for the use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents
. Brazil: Ministry of Health of Brazil; 2007. pp. 1–209.
16. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615–1627.
17. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335–341.
18. Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601–610.
19. Nery JAC, Sampaio EP, Galhardo MC, Perisse AR, Vieira LM, Sales AM, et al
. M. leprae
-HIV co-infection: pattern of immune response in vivo and in vitro. Indian J Lepr 2000; 72:155–167.